Vaccentis

Vaccentis is a Swiss-based biotechnology company specializing in personalized medicine and immunotherapy. The company focuses on the development and commercialization of autologous tumor vaccines and microbial therapies for oncology and gastroenterology. Its flagship product, RenalCell, is an adjuvant autologous tumor vaccine designed to prevent recurrence in patients with renal cell carcinoma. Additionally, through its subsidiaries, Vaccentis provides microbial-based treatments like Colibiogen for inflammatory and functional bowel disorders. The company operates a vertically integrated model, encompassing research, development, and specialized manufacturing of patient-specific therapies.